Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Directed disruption of IL2 aggregation and receptor binding sites produces designer biologics with enhanced specificity and improved production capacity. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1146/annurev.immunol.26.021607.090357
10.1146/annurev.immunol.26.021607.090357 · External reference
10.1038/ni.2649
10.1038/ni.2649 · External reference
10.1016/j.immuni.2018.10.010
10.1016/j.immuni.2018.10.010 · External reference
10.1038/ni.2886
10.1038/ni.2886 · External reference
10.1038/ni1263
10.1038/ni1263 · External reference
10.1146/annurev-immunol-032713-120211
10.1146/annurev-immunol-032713-120211 · External reference
10.1038/nri3605
10.1038/nri3605 · External reference
10.1084/jem.20122759
10.1084/jem.20122759 · External reference
Context-dependent effects of IL-2 rewire immunity into distinct cellular circuits
2022 · External reference
10.1016/j.jaci.2015.12.1314
10.1016/j.jaci.2015.12.1314 · External reference
10.1016/j.jaci.2018.10.068
10.1016/j.jaci.2018.10.068 · External reference
The fate of interleukin-2 after in vivo administration
10.4049/jimmunol.130.5.2203 · 1983 · External reference
In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2
10.4049/jimmunol.134.1.157 · 1985 · External reference
The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2
10.1002/1097-0142(19950815)76:4<687::aid-cncr2820760424>3.0.co;2-m · 1995 · External reference
10.1038/s41551-021-00797-8
10.1038/s41551-021-00797-8 · External reference
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
10.1038/ncomms15373 · 2017 · External reference
10.1126/scisignal.adg0699
10.1126/scisignal.adg0699 · External reference
10.1016/j.immuni.2015.04.015
10.1016/j.immuni.2015.04.015 · External reference
10.4049/jimmunol.1800907
10.4049/jimmunol.1800907 · External reference
10.1038/s41590-022-01208-z
10.1038/s41590-022-01208-z · External reference
Directed evolution of super-secreted variants from phage-displayed human Interleukin-2
10.1038/s41598-018-37280-5 · 2019 · External reference
10.1038/nature10975
10.1038/nature10975 · External reference
Interleukin-2 superkines by computational design
10.1073/pnas.2117401119 · 2022 · External reference
Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist
10.7554/elife.65777 · 2021 · External reference
Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity
10.1093/protein/gzg111 · 2003 · External reference
10.4049/jimmunol.1201895
10.4049/jimmunol.1201895 · External reference
Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles
10.1038/s42003-023-05188-0 · 2023 · External reference
An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice
10.1126/sciimmunol.aba5264 · 2020 · External reference
10.1097/cji.0b013e3181b528da
10.1097/cji.0b013e3181b528da · External reference
10.1016/j.immuni.2015.04.018
10.1016/j.immuni.2015.04.018 · External reference
10.4049/jimmunol.1700433
10.4049/jimmunol.1700433 · External reference
10.1038/s41586-021-03861-0
10.1038/s41586-021-03861-0 · External reference
A Treg-Selective IL-2 mutein prevents the formation of factor viii inhibitors in hemophilia mice treated with factor VIII gene therapy
10.3389/fimmu.2020.00638 · 2020 · External reference
Dynamic changes in the regulatory T-cell heterogeneity and function by murine IL-2 mutein
2020 · External reference
10.1038/s41586-018-0830-7
10.1038/s41586-018-0830-7 · External reference
10.1126/science.aar3246
10.1126/science.aar3246 · External reference
10.1038/s41467-022-31130-9
10.1038/s41467-022-31130-9 · External reference
Prediction and reduction of the aggregation of monoclonal antibodies
10.1016/j.jmb.2017.03.014 · 2017 · External reference
10.1371/journal.pcbi.1000476
10.1371/journal.pcbi.1000476 · External reference
SolubiS: optimizing protein solubility by minimal point mutations
10.1007/978-1-4939-8820-4_21 · 2019 · External reference
Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors
10.1126/science.1117893 · 2005 · External reference
Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4)
10.4049/jimmunol.138.6.1813 · 1987 · External reference
Structural hot spots for the solubility of globular proteins
10.1038/ncomms10816 · 2016 · External reference
10.3389/fimmu.2020.01106
10.3389/fimmu.2020.01106 · External reference
10.1158/1078-0432.ccr-14-1520
10.1158/1078-0432.ccr-14-1520 · External reference
Managing toxicities of high-dose interleukin-2
2002 · External reference
10.1182/bloodadvances.2019000631
10.1182/bloodadvances.2019000631 · External reference
10.1158/1078-0432.ccr-13-3205
10.1158/1078-0432.ccr-13-3205 · External reference
10.2478/rir-2023-0021
10.2478/rir-2023-0021 · External reference
10.1016/s2665-9913(19)30018-9
10.1016/s2665-9913(19)30018-9 · External reference
10.1073/pnas.252756299
10.1073/pnas.252756299 · External reference
10.1126/science.1109745
10.1126/science.1109745 · External reference
10.1073/pnas.0511161103
10.1073/pnas.0511161103 · External reference
Protein aggregation and amyloidosis: confusion of the kinds?
10.1016/j.sbi.2006.01.011 · 2006 · External reference
10.1038/nbt1012
10.1038/nbt1012 · External reference
10.1016/j.jmb.2004.06.088
10.1016/j.jmb.2004.06.088 · External reference
10.1093/nar/gki387
10.1093/nar/gki387 · External reference
Protein aggregation and amyloid fibril formation prediction software from primary sequence: towards controlling the formation of bacterial inclusion bodies
10.1111/j.1742-4658.2011.08164.x · 2011 · External reference
10.1002/cpz1.589
10.1002/cpz1.589 · External reference
10.1016/j.immuni.2024.05.023
10.1016/j.immuni.2024.05.023 · External reference
